Drugs / NM32-2668
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06299163 | May 2024 → Apr 2025 | endometrial cancer, fallopian tube carcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma +9 | Numab Therapeutics AG | Terminated | No outcome recorded Stop: Business |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NM32-2668 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06299163 ↗ |